CannPal Animal Therapeutics (ASX: CP1)
CannPal Animal Therapeutics (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. www.cannpal.com
CannPal closer to commercialisation of DermaCann after it reduces canine dermatitis in study
CannPal Animal Therapeutics (ASX: CP1) is a step closer to commercialisation after its oral hemp-based CBD nutraceutical DermaCann was shown to ...
CannPal secures commercial rights to CSIRO’s MicroMAX technology
Following an 18 month review, CannPal (ASX: CP1) has secured exclusive rights to commercialise the Commonwealth Scientific and Industrial Resear...
CannPal Animal Therapeutics to conduct veterinary research alongside the University of Melbourne
CannPal Animal Therapeutics (ASX: CP1) is looking to develop and broaden its research pipeline after announcing that it has signed a memorandum ...
CannPal and CSIRO to advance cannabinoid medicines for pets
Animal health company CannPal Animal Therapeutics (ASX: CP1) has entered into a research agreement with the Commonwealth Scientific and Industri...
CannPal secures Australian cannabis import licence to bring in formulations for research
CannPal Animal Therapeutics (ASX: CP1) has secured its import licence from the Australian Government’s Office of Drug Control, which will allow ...
Debutant ‘pot stock’ CannPal gains NSW Govt approval for cannabis-based trials in dogs
The New South Wales Department of Health has approved CannPal Animal Therapeutics’ (ASX: CP1) application to possess and supply cannabidiol and ...